Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate dose-ranging versus Aredia in breast cancer with osteolytic bone metastases
ISRCTN29188871Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Jan 1995
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zoledronate and pamidronate in breast cancer (4 arms), sponsored by Cancer Research UK. Primary endpoints: Safety and Efficacy. Started Jan 1995; status: completed.
02
Drugs
zoledronatepamidronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN29188871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29188871.